erlotinib hydrochloride has been researched along with nvp-tae684 in 1 studies
Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (nvp-tae684) | Trials (nvp-tae684) | Recent Studies (post-2010) (nvp-tae684) |
---|---|---|---|---|---|
4,353 | 786 | 3,033 | 74 | 0 | 63 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kita, K; Mano, H; Matsumoto, K; Nakade, J; Nakagawa, T; Nakamura, T; Nanjo, S; Soda, M; Takeuchi, S; Uenaka, T; Yamada, T; Yano, S | 1 |
1 other study(ies) available for erlotinib hydrochloride and nvp-tae684
Article | Year |
---|---|
Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Crizotinib; Drug Resistance, Neoplasm; Endothelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Fibroblasts; Gene Amplification; Hepatocyte Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Mice; Mice, SCID; Mutation, Missense; Oncogene Proteins, Fusion; Paracrine Communication; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2012 |